{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825894746879744.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1159/000076844"}},{"identifier":{"@type":"URI","@value":"https://www.karger.com/Article/Pdf/76844"}}],"dc:title":[{"@value":"Photodynamic Therapy with Verteporfin for Polypoidal Choroidal Vasculopathy of the Macula"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><i>Purpose:</i> Indications for photodynamic therapy (PDT) have increased from age-related macular degeneration with choroidal neovascularization (CNV), containing more than 50% of the classic component, to occult CNV, myopic CNV and CNV due to ocular histoplasmosis syndrome. In the present study, the effect of PDT with verteporfin was examined in polypoidal choroidal vasculopathy (PCV) of the macula. <i>Methods:</i> PDT was performed in 9 eyes with PCV of the macula. Fundus examination, fluorescein angiography, and indocyanine green angiography were performed before PDT and 3 months after PDT in all eyes. Optical coherence tomography was performed in 6 eyes. <i>Results:</i> After the initial PDT, visual acuity was stabilized or improved in 8 eyes (89%), polypoid elements were obliterated in 7 eyes (78%), and vascular nets were reduced in 8 eyes (89%). Of 6 eyes that received optical coherence tomography, pigment epithelium detachment was reduced or disappeared in all eyes except 1, which developed a disciform scar. An additional PDT was performed in 4 eyes to decrease vascular leakage. During the follow-up period of 3–18 months, no reactivation of PCV was observed. <i>Conclusion:</i> PDT offers an effective way of treating PCV of the macula, by obliterating polypoid elements of the PCV. However, long-term follow-up is needed.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825894746879744","@type":"Researcher","foaf:name":[{"@value":"Sung Chul Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894746879745","@type":"Researcher","foaf:name":[{"@value":"Youl Seok Seong"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894746879873","@type":"Researcher","foaf:name":[{"@value":"Sung Soo Kim"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894746879872","@type":"Researcher","foaf:name":[{"@value":"Hyung Jun Koh"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825894746879874","@type":"Researcher","foaf:name":[{"@value":"Oh Woong Kwon"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00303755"},{"@type":"EISSN","@value":"14230267"}],"prism:publicationName":[{"@value":"Ophthalmologica"}],"dc:publisher":[{"@value":"S. Karger AG"}],"prism:publicationDate":"2004","prism:volume":"218","prism:number":"3","prism:startingPage":"193","prism:endingPage":"201"},"reviewed":"false","dc:rights":["https://www.karger.com/Services/SiteLicenses","https://www.karger.com/Services/SiteLicenses"],"url":[{"@id":"https://www.karger.com/Article/Pdf/76844"}],"createdAt":"2004-04-23","modifiedAt":"2025-04-24","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004233403476864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711022807424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679221784576","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The prognosis of cases with massive subretinal hemorrhage after photodynamic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1520010380908088320","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Photodynamic Therapy in Macular Diseases of Asian Populations: When East Meets West"},{"@language":"ja-Kana","@value":"Photodynamic Therapy in Macular Diseases of Asian Populations When East Meets West"}]},{"@id":"https://cir.nii.ac.jp/crid/1521136280304532608","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration"},{"@language":"ja-Kana","@value":"Clinical investigation Effect of combined treatment with sub Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1521136280486107520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area"},{"@language":"ja-Kana","@value":"Clinical investigation Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area"}]},{"@id":"https://cir.nii.ac.jp/crid/1521699230361010688","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigations: Role of photodynamic therapy in polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Clinical investigations Role of photodynamic therapy in polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1521980705254530816","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Clinical investigation Three year follow up results of photodynamic therapy for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1522262180053820800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy"},{"@language":"ja-Kana","@value":"Clinical investigation Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1523669555364359168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity"}]},{"@id":"https://cir.nii.ac.jp/crid/1523951030320826752","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence"},{"@language":"ja-Kana","@value":"Clinical investigation Photodynamic therapy for polypoidal choroidal vasculopathy vaso occlusive effect on the branching vascular network and origin of recurrence"}]},{"@id":"https://cir.nii.ac.jp/crid/1524232505490891008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age-Related Macular Degeneration"},{"@language":"ja-Kana","@value":"Polypoidal Choroidal Vasculopathy and Retinochoroidal Anastomosis in Japanese Patients Eligible for Photodynamic Therapy for Exudative Age Related Macular Degeneration"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1159/000076844"},{"@type":"CROSSREF","@value":"10.1038/eye.2011.110_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-007-0452-3_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1136/bjophthalmol-2018-312419_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.2152/jmi.55.231_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-013-0245-9_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-005-0259-z_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-005-0337-2_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-007-0501-y_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-010-0886-x_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-008-0551-9_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-008-0582-2_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"},{"@type":"CROSSREF","@value":"10.1007/s10384-009-0703-6_references_DOI_PV2HdNyy2g4HdTy3g5Z13RhAa99"}]}